Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
gene editing
Biotech
Moderna exits Metagenomi gene editing deal worth $3B biobucks
Earlier this year, Metagenomi had the spotlight with a $93.7 million IPO. Now, Moderna is exiting a partnership worth up to $3 billion in biobucks.
Gabrielle Masson
May 1, 2024 4:00pm
Regeneron signs Mammoth gene editing deal worth $100M upfront
Apr 25, 2024 8:49am
Profluent combines LLMs, CRISPR for open-source AI gene editing
Apr 23, 2024 2:00pm
Ex-bluebird execs hope to fly startup to delivery tech heights
Apr 9, 2024 7:00am
Verve halts VERVE-101 enrollment, focuses on 2nd PCSK9 editor
Apr 2, 2024 7:00am
Intellia opts out of hemophilia gene editing work with Regeneron
Mar 22, 2024 11:21am